Abstract: A dispersion of exfoliated particles which includes at least one nitrogen-containing basic compound (A) which is a tertiary amine or a quaternary ammonium hydroxide having at least one alkyl group having 3 or 4 carbon atoms, and in which exfoliated particles (C) produced by interlayer-exfoliating a proton-type layered polysilicate compound (B) are dispersed in an aqueous solution (D) having 10 vol % to 90 vol % of an alcohol having 1 to 3 carbon atoms; and a film-forming composition, a porous body-forming composition, an LB film, a coating film, a free-standing membrane, a proton conductor, an electrolyte membrane for fuel cells, and a porous body each containing exfoliated particles.

Abstract: An inactivated whole-virus influenza vaccine may have its antibody-inducing ability is maintained or enhanced and may cause fewer side reactions. A method for preparing an inactivated whole-virus influenza vaccine may use an embryonated chicken egg method, including subjecting a virus solution including a whole influenza virus collected from embryonated chicken eggs to a hypotonic treatment.

Abstract: An object of the present invention is to reveal a role of a stem cell control factor including Matrin-3 in cancer exhibiting neural differentiation including small cell lung cancer, and develop a medicine useful for treating cancer and the like based on the role. Among cancers having the cancer stem cell controlling mechanism, in cancer exhibiting the differentiation potency, the peculiar balance where both of expression of a stem cell maintenance factor and expression of a differentiation promoting factor are higher as compared with normal cells is retained. Additionally, in undifferentiated cancer, the peculiar balance where expression of a stem cell maintenance factor is higher as compared with normal cells is retained. In cancer in which the cancer stem cell controlling mechanism exists, these peculiar balances of a stem cell control factor different from the balance of normal cells exist.

Abstract: It is an object of the present invention to provide antibodies against coronavirus (SARS-CoV-2). It is also an object of the present invention to provide a pharmaceutical composition against coronavirus infection using the antibody. According to the present invention, an antibody or antigen-binding fragment thereof that binds to the receptor-binding domain present in the spike protein of coronavirus and is capable of neutralizing the coronavirus, and a pharmaceutical composition for the prevention or treatment of coronavirus infection containing the antibody or antigen-binding fragment, are provided.

Abstract: [Object] To clarify the mechanism associated with neuropathy in methylmalonic acidemia and to develop a new therapeutic drug or the like for neuropathy in organic acidemia on the basis of this finding. [Solving Means] The inventors established technologies for the establishment of iPS cells derived from a methylmalonic acidemia patient and establishment of a stable maintenance and culturing method using peripheral blood lymphocytes of a methylmalonic acidemia patient, and for the differentiation of methylmalonic acidemia patient-derived iPS cells into nerve cells. The inventors made clear that neuropathy in organic acidemia can be treated and prevented by replenishing cAMP using a series of these experiment technologies. The drug of the invention treats or prevents neuropathy by increasing cAMP in organic acidemia.

Abstract: The present invention provides a method for highly sensitively and highly specifically detecting a kidney cancer. According to the present invention, there is provided, for example, a method for detecting a kidney cancer in a subject, comprising diluting a urine sample obtained from the subject at a predetermined ratio, and determining whether or not nematodes exhibit attraction behavior toward the diluted urine sample, wherein the predetermined ratio is 200 or more.

Abstract: Provided are a transthyretin tetramer stabilizing agent and a preventing agent or progression suppressing agent for transthyretin amyloidosis. The present invention relates to a transthyretin tetramer stabilizing agent including glabridin, glabrene, and glabrol, and to a preventing agent or progression suppressing agent for transthyretin amyloidosis including glabridin, glabrene, and glabrol.

Abstract: Provided are a transthyretin tetramer stabilizing agent and a preventing agent or progression suppressing agent for transthyretin amyloidosis. The present invention relates to a transthyretin tetramer stabilizing agent including a hydrophobic licorice extract containing a licorice glabra polyphenol, and to a preventing agent or progression suppressing agent for transthyretin amyloidosis including a hydrophobic licorice extract containing a licorice glabra polyphenol.

Abstract: A mucosal adjuvant may have high mucosal immunogenicity and high safety and be useful in the preparation of mucosal vaccines, and a mucosal vaccine composition may include the same. Such mucosal adjuvant may include TGDK. A method for preparing the mucosal vaccine composition may include mixing TGDK with an immunogen.

Abstract: An exemplary composition can be provided which includes an identified substance that induced cell reprogramming. Cells can also be provided having pluripotency having high safety when applied to regenerative medicine, using the composition, and a production method therefor. A cell reprogramming-inducing composition can include at least one 30S ribosome protein selected from the group consisting of 30S ribosome protein S2, 30S ribosome protein S8 and 30S ribosome protein S15 as a substance that reprograms cells derived from a mammalian animal is provided. Further, an exemplary production method for cells having pluripotency from somatic cells using the composition can be provided.

Abstract: An RNA methyltransferase inhibitor comprising sulfonamide-based compounds and/or pyrazoline-based compounds is provided

Abstract: An object of the present invention is to provide a method for cryopreserving rat sperms and an in vitro fertilization method using cryopreserved rat sperms. The present invention provides a method for preparing cryopreserved rat sperms, characterized by comprising the following steps: step a: a preparation step of collecting rat sperms from the rat cauda epididymis to prepare a sperm suspension, step b: a cooling step of cooling the sperm suspension to about 1° C. or lower, and step c: a freezing step of freezing the rat sperm suspension cooled to about 1° C. or lower.

Abstract: An object of the present invention is to provide a novel plant growth inhibiting agent and a plant growth inhibiting method using the same. The plant growth inhibiting agent of the present invention comprises, as an active ingredient, a compound represented by the following formula (I?) and/or a salt thereof. In the formula (I?), R1a represents a substituted or unsubstituted C1 to C20 alkyl group, a substituted or unsubstituted C6 to C14 aryl group, a substituted or unsubstituted C3 to C13 heteroaryl group, or the like; R2 represents a substituted or unsubstituted C1 to C20 alkylene group, a substituted or unsubstituted C6 to C14 arylene group, or the like; R3a represents OH, a substituted or unsubstituted C1 to C6 alkoxy group, or the like; X represents an oxygen atom; Y represents a substituent; q represents any integer of 0 to 3; n represents 0 or 1; and m represents 0 or 1.

Abstract: [Problem] To provide a nuclear magnetic resonance diagnostic agent that has a lower toxicity to organisms and reduced side effects and yet has a site specificity toward a specific cell, tissue, organ, etc. [Solution] When ALA or an ALA derivative is administered in vivo, a metabolite thereof is accumulated in a specific cell, tissue, organ, etc. Focusing on this phenomenon, a nuclear magnetic resonance analysis was performed on a site wherein the metabolite of ALA that had been administered in vivo would be possibly accumulated. As a result, it was surprisingly found that ALA and an ALA derivative are useful as a diagnostic agent whereby the aforesaid problem can be solved.

Abstract: Provided is an insulin secretion-promoting agent comprising, as an active ingredient, a triglyceride represented by the following formula (I): wherein R1, R2 and R3 each denotes a saturated fatty acid residue, at least one of which is a pentadecanoic acid residue. An insulin secretion-promoting action of the pentadecanoic acid triglyceride at the time of elevated blood glucose level is discovered, and pharmaceuticals and health foods for improving blood glucose level and diabetes are provided using this triglyceride.

Abstract: CD4 mimic compounds having improved efficacy for anti-HIV treatment and more improved pharmacokinetics are provided. The compounds are represented by formula (I): wherein R1 is C2H4(OC2H4)n—OCH3 or CmH2m+1; R2 is O or NH; n is 3 to 25; and m is 4 to 22, or a salt thereof. HIV infection inhibitor compositions including the compound or a salt thereof as an active ingredient are also disclosed.

Abstract: A purpose of the present invention is to provide an optical measurement system or the like suitable for optical measurement of nucleic acids, proteins, etc. In a first aspect of the present invention, an optical measurement system that provides optical sample measurement comprises: an optical cell having a sample-holding hollow portion; and a light source unit that emits broadband light containing first and second light to the optical cell. The optical cell includes: a first light guide where light passes through a first transparent portion that transmits the first light more readily than the second light and the hollow portion without passing through a second transparent portion that transmits the second light more readily than the first light; and a second light guide that differs from the first light guide, in which light passes through the second transparent portion and the hollow portion without passing through the first transparent portion.

Abstract: Provided is a pharmaceutical agent for enhancing absorption efficiency of a drug through the mucosal epithelial layer. A pharmaceutical agent for transmucosal administration comprises as an active ingredient a drug compound to which a podocalyxin targeting molecule is bound.

Abstract: An allocation method executed by a computer includes dividing each of a plurality of pieces of time-series data into a plurality of segments, allocating a label to each of the pieces of time-series data based on features of each segment in the pieces of time-series data, and allocating a predetermined segment in time-series data, included in the pieces of time-series data, with a label allocated to the time-series data to which the predetermined segment belongs.

Abstract: The present invention provides a column filler for liquid chromatography that has a great adsorption capacity, adjustable adsorption selectivity, and high shape retainability and therefore is usable for measurement of various substances and capable of achieving excellent separation performance and a high filling rate in a column when used as a column filler for liquid chromatography. Provided is a column filler for liquid chromatography including carbon-coated porous particles, the carbon-coated porous particles including porous particles each having a coating layer containing an amorphous carbon on a surface.